BioInfra Life Science바이오인프라생명과학

BioInfra Life Science is a small KONEX-listed diagnostics and biotech firm whose shares have fallen sharply over the past year, with no financial statements in the data to judge its current business.

The company develops blood-based multi-marker cancer screening tests, runs a diagnostic testing hospital network, and is working on gene-based therapies and an ultrasound drug delivery platform. The shares closed at ₩95 on 2026-10-23, down 60.4% over one year and near the 52-week low of ₩79, giving a market value of about ₩2.6B. The data contains no annual or trailing financial results and no valuation multiples, so the current financial position cannot be assessed from it.

What stands out

• The share price is ₩95, well below the 52-week high of ₩355 and close to the low of ₩79, with returns of -5% over one month, -29.6% over three months and -60.4% over one year.
• No annual or trailing-twelve-month financial statements are included in the data, so revenue, profit and cash flow are unknown.
• Valuation ratios such as P/E, P/B and EV/EBITDA are unavailable, and the dividend yield is 0%.
• Foreign ownership is 0% now and 60 days ago, and 20-day net flows show only retail buying of about ₩19.6B with no foreign or institutional flows.
• Recent filings are mostly governance items: a change of CEO and head office location, an AGM, an extraordinary shareholders' meeting, and an IR event. No news headlines were provided.

What to watch

• Upcoming annual or interim financial filings, which would be needed to judge revenue, profitability and cash position.
• Outcome of the shareholders' meeting called in mid-2026 and any further filings on management or head office changes.
• Any update on the diagnostic testing business, overseas partner activity, or the drug delivery and gene therapy programmes, none of which are quantified in the data.